In this article, we will discuss Durvalumab (Biliary Tract Cancer). So, let’s get started.
Biliary Tract Cancer
The safety of Durvalumab in combination with gemcitabine and cisplatin in locally advanced or metastatic BTC was evaluated in TOPAZ-1, a randomized, double-blind, placebo-controlled, multicenter trial. A total of 338 patients received Durvalumab 1,500 mg in combination with gemcitabine and cisplatin every 3 weeks up to 8 cycles followed by Durvalumab 1,500 mg every 4 weeks until disease progression or unacceptable toxicity. Patients with active or prior documented autoimmune or inflammatory disorders, HIV infection or other active infections, including tuberculosis or hepatitis C were ineligible.